Popular weight-loss and diabetes medications such as Ozempic and Mounjaro are linked to a modest increase in the risk of hair loss, according to recent medical studies. While the overall risk remains uncommon, researchers caution that these GLP-1 receptor agonists present side effects that patients and clinicians should monitor closely during treatment.
The rapid rise of GLP-1 receptor agonists has transformed chronic disease management, offering powerful tools for blood sugar control and weight reduction. This drug class includes semaglutide, sold under brand names such as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. Yet as millions of patients begin taking these medications, researchers are uncovering a broader picture of how the drugs interact with the human body. Recent investigations point not only to potential hair loss risks, but also to unexpected neurological and oncological findings that warrant careful clinical evaluation.
Investigating Alopecia Rates Among GLP-1 Users
Hair loss has previously been reported as a possible side effect of GLP-1 receptor agonists, particularly medications containing semaglutide or tirzepatide. However, there has been limited research directly comparing the risk among GLP-1 users with the risk among patients taking other diabetes treatments. A study published by The BMJ on July 22, 2026, provides a detailed comparison regarding hair loss among patients. To investigate, researchers analyzed electronic health records from the University of Pennsylvania Health System (Penn Medicine). They compared alopecia rates among adults with type 2 diabetes who began treatment with GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors.
A study led by researchers at the University of Pennsylvania, published in The BMJ, found that after two or more years of treatment, people using GLP-1 drugs had 37% higher odds of developing alopecia than users of SGLT-2 diabetes medications, and 68% higher odds compared with users of DPP-4 inhibitors.
Despite the increase, the overall number of cases remained low, with approximately three to nine new cases per 1,000 people each year. Similar findings in other research include another study involving more than one million participants worldwide, published in the Journal of the American Academy of Dermatology, which also found higher rates of several forms of alopecia among GLP-1 users compared with patients taking metformin. A third study by analytics company nference compared more than 11,000 patients taking tirzepatide with an equal number using semaglutide, finding new-onset alopecia occurred in 4.24% of patients taking tirzepatide and 3.33% of patients taking semaglutide.
Exploring Underlying Mechanisms and Rare Optic Risks
The exact biological pathways connecting GLP-1 medications to hair loss are not yet fully established. Researchers point out that rapid weight loss is a well-established trigger for increased hair shedding. However, some findings suggest weight loss may not be the only driver.
Beyond dermatological concerns, other medical teams are scrutinizing rare events. Doctors in Massachusetts have found a link between the drug’s active ingredient semaglutide and a higher risk of a rare condition that can cause blindness called nonarteritic anterior ischemic optic neuropathy (NAION). The findings do not prove a causal connection between the two, however, and more research is needed to know for certain, the researchers say. The study was conducted by ophthalmologists at Harvard Medical School and Mass Eye and Ear, a specialty hospital focused on eye issues affiliated with Harvard. The team was inspired to look into the potential link after they had come across three patients who began to lose their vision from NAION within a week’s time. This would already be strange, since NAION isn’t very common, with estimates suggesting that about 6,000 new cases in the U.S. occur annually, but all three patients were also taking semaglutide. The researchers decided to do a deep dive into their existing data, analyzing the medical records of about 17,000 Mass Eye and Ear patients dating back to 2017, when the first semaglutide-based medication Ozempic was approved for use as a treatment for type 2 diabetes.
Broader Health Outcomes and Future Clinical Surveillance
More evidence suggests that medications such as Ozempic and Mounjaro, originally developed for diabetes and then approved for obesity, have benefits that go beyond these conditions. Those include a lower risk of 10 cancers, protection against heart and kidney diseases, and a reduction in systemic inflammation, according to recently published research.
Some of these protective effects likely result from patients’ weight loss when taking these medications, but the drugs appear to have other effects that improve health independent of the weight loss. As Daniel Drucker, a physician-scientist at the Lunenfield-Tanenbaum Research Institute at Mt. Sinai Hospital in Toronto, states in a commentary published Thursday in Science: The cardioprotective effect of semaglutide observed in people with obesity developed within months of drug initiation, well before meaningful weight loss had been achieved in most trial participants
in one 2022 trial. He further writes: The initial chapter of GLP-1 innovation focused on glucose control, and later, weight loss. Subsequent waves seem likely to improve health outcomes in people with a range of chronic disorders.
Physicians emphasize that observational studies cannot prove direct cause and effect, and knowing about the possible side effect could help patients and clinicians make more informed treatment decisions together.
Keep reading
